Free Trial

Soleno Therapeutics (SLNO) Competitors

Soleno Therapeutics logo
$51.21 -2.41 (-4.50%)
Closing price 03:59 PM Eastern
Extended Trading
$51.14 -0.06 (-0.12%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLNO vs. FEMY, IMVT, SOLV, PEN, STVN, GKOS, IRTC, BLCO, TMDX, and NVST

Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical" sector.

Soleno Therapeutics vs. Its Competitors

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Soleno Therapeutics has a beta of -2.71, suggesting that its stock price is 371% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.63, suggesting that its stock price is 363% less volatile than the S&P 500.

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 11.5% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A-$175.85M-$4.14-12.37
Femasys$1.63M7.34-$18.82M-$0.86-0.43

Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Soleno TherapeuticsN/A -73.74% -56.67%
Femasys -1,113.72%-713.74%-152.60%

Soleno Therapeutics currently has a consensus target price of $115.09, suggesting a potential upside of 124.75%. Femasys has a consensus target price of $7.33, suggesting a potential upside of 1,898.18%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
3.08
Femasys
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Soleno Therapeutics had 32 more articles in the media than Femasys. MarketBeat recorded 38 mentions for Soleno Therapeutics and 6 mentions for Femasys. Femasys' average media sentiment score of 0.74 beat Soleno Therapeutics' score of 0.59 indicating that Femasys is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Soleno Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
14 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Femasys
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Soleno Therapeutics and Femasys tied by winning 8 of the 16 factors compared between the two stocks.

Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLNO vs. The Competition

MetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.72B$2.83B$5.75B$10.27B
Dividend YieldN/A57.24%5.72%4.60%
P/E Ratio-12.3723.2875.1726.41
Price / SalesN/A528.92455.9688.49
Price / CashN/A27.5625.8129.91
Price / Book9.025.4013.256.28
Net Income-$175.85M$32.95M$3.29B$270.38M
7 Day Performance-29.17%0.20%0.76%2.79%
1 Month Performance-28.51%4.07%4.63%6.00%
1 Year Performance-3.09%-2.88%73.44%25.97%

Soleno Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLNO
Soleno Therapeutics
4.433 of 5 stars
$51.21
-4.5%
$115.09
+124.8%
+1.5%$2.72BN/A-12.3730Positive News
Short Interest ↑
Analyst Revision
FEMY
Femasys
3.0932 of 5 stars
$0.36
-0.4%
$7.33
+1,965.1%
-65.0%$11.57M$1.63M-0.4130Short Interest ↑
Gap Up
IMVT
Immunovant
2.4547 of 5 stars
$14.69
-0.9%
$35.20
+139.6%
-45.5%$2.56BN/A-5.15120Positive News
SOLV
Solventum
2.1097 of 5 stars
$73.15
+0.7%
$85.75
+17.2%
+4.7%$12.67B$8.25B33.8622,000Analyst Forecast
PEN
Penumbra
4.671 of 5 stars
$272.96
+0.5%
$300.47
+10.1%
+46.3%$10.63B$1.19B72.604,500Positive News
STVN
Stevanato Group
N/A€23.14
-1.4%
N/A+37.2%€7.01B€1.19B42.855,521Gap Up
GKOS
Glaukos
4.6491 of 5 stars
$95.86
-0.7%
$127.42
+32.9%
-34.5%$5.50B$383.48M-58.10780Positive News
IRTC
iRhythm Technologies
1.2096 of 5 stars
$169.98
-0.9%
$163.82
-3.6%
+134.7%$5.46B$591.84M-58.012,000Positive News
BLCO
Bausch + Lomb
2.0891 of 5 stars
$14.63
+0.6%
$15.56
+6.3%
-2.2%$5.18B$4.79B-18.7613,500Positive News
TMDX
TransMedics Group
2.5734 of 5 stars
$114.96
-1.5%
$123.00
+7.0%
-24.3%$3.92B$441.54M59.57210
NVST
Envista
3.8278 of 5 stars
$21.15
-0.5%
$20.92
-1.0%
+8.4%$3.52B$2.51B66.0812,300Positive News

Related Companies and Tools


This page (NASDAQ:SLNO) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners